The 53 references in paper O. Korennova Yu., L. Shukil' V., S. Mal'tsev N., I. Klinyshkov A., N. Leganova M., E. Turusheva A., T. Kropotina V., О. Кореннова Ю., Л. Шукиль В., С. Мальцев Н., И. Клинышков А., Н. Леганова М., Е. Турушева А., Т. Кропотина В. (2016) “Фармакоэкономическое обоснование применения генно-инженерных биологических препаратов в амбулаторных условиях // PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS” / spz:neicon:pharmacoeconomics:y:2016:i:1:p:39-48

1
Balabanova R.M., Amirdzhanova V.N., Nasonov E.L. Nauchpraktich. revmatol. 2012; T. 50 (6): 10-14.
(check this in PDF content)
2
Bunchuk N.V. Nauch-praktich. revmatol. 2006; 4: 4-10.
(check this in PDF content)
3
Vorob'ev P.A., Avksent'eva M.V., Yur'ev A.S., Sura M.V. Clinical and economic analysis (assessment, selection of medical technology and health care quality management) [Kliniko-ekonomicheskii analiz (otsenka, vybor meditsinskikh tekhnologii i upravlenie kachestvom meditsinskoi pomoshchi) (in Russian)]. Moscow. 2004; 404 s.
(check this in PDF content)
4
Issue of Clinical analysis in rheumatological practice. Institution of the Russian Academy of Medical Sciences' Research Institute of Rheumatology RAMS them. VA Nasonova "All-Russian public organization" Association of Rheumatology Russia [Vypusk klinicheskikh razborov v revmatologicheskoi praktike. Uchrezhdenie Rossiiskoi akademii meditsinskikh nauk «Nauchno-issledovatel'skii institut revmatologii RAMN im. V.A. Nasonovoi», obshcherossiiskaya obshchestvennaya organizatsiya «Assotsiatsiya revmatologov Rossii» (in Russian)]. 2013; 136 s.
(check this in PDF content)
5
Godzenko A.A., Korsakova Yu.L., Badokin V.V. Methods for evaluation of inflammatory activity and the effectiveness of therapy in spondylitis [Metody otsenki vospalitel'noi aktivnosti i effektivnosti terapii pri spondiloartritakh (in Russian)]. Moscow. 2013; 48 s.
(check this in PDF content)
6
Map-notification of side effects, adverse reaction or lack of expected therapeutic effect of the drug" URL: http://roszdravnadzor.ru/ drugs/monitpringlp/documents/547. Accessed: 18.01.15
(check this in PDF content)
7
Nasonov E.L., Karateev D.E., Balabanova R.M. Rheumatoid arthritis. VA Nasonova Ed. EL Nasonova. Rheumatology. National leadership [Revmatoidnyi artrit. V.A. Nasonovoi Pod red. E.L. Nasonova. Revmatologiya. Natsional'noe rukovodstvo (in Russian)]. Moscow. 2008; 290-331.
(check this in PDF content)
8
Nasonov E.L., Karateev D.E. Nauch-praktich. revmatol. 2013; 51 (2): 163-169.
(check this in PDF content)
9
Resolution of the Government of the Omsk region on December 24, 2014 No 330-p "On the Territorial program of state guarantees of free medical care to citizens in Omsk Region for 2015 and the planning period of 2016 and 2017" [Postanovlenie Pravitel'stva Omskoi oblasti ot 24 dekabrya 2014 g. No 330-p «O Territorial'noi programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi v Omskoi oblasti na 2015 god i na planovyi period 2016 i 2017 godov» (in Russian)].
(check this in PDF content)
10
The Ministry of Health of Russia Order dated November 12, 2012 No 900 n "On approval of the provision of medical care to adult population on the profile of" Rheumatology" [Prikaz Minzdrava Rossii ot 12 noyabrya 2012 g. No 900n «Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi vzroslomu naseleniyu po profilyu «Revmatologiya» (in Russian)].
(check this in PDF content)
11
The Russian Ministry of Health Order of March 11, 2013 No
(check this in PDF content)
12
n "On Approval of the Requirements for the organization and execution of works (services) in the provision of primary health care, specialized (including high-tech), Emergency (including a specialized ambulance), palliative medical care, medical care at a spa treatment, in medical examinations, medical examinations, medical examinations and sanitary and anti-epidemic (preventive) measures in the framework of the provision of health care in transplantation (transplantation) of organs and (or) tissues, treatment of donor blood and (or) its components for medical purposes. ["Prikaz Minzdrava Rossii ot 11 marta 2013 g. No 121n «Ob utverzhdenii Trebovanii k organizatsii i vypolneniyu rabot (uslug) pri okazanii pervichnoi mediko-sanitarnoi, spetsializirov
(check this in PDF content)
13
Rebrova O.Yu. Statistical analysis of medical data. The application package STATISTICA applications [Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA (in Russian)]. Moscow. 2002; 312 s.
(check this in PDF content)
14
Rheumatology. Clinical guidelines. Ed. Acad. RAMS EL Nasonova. 2nd ed. [Revmatologiya. Klinicheskie rekomendatsii. Pod red. akad. RAMN E.L. Nasonova. 2-e izd (in Russian)]. Moscow. 2010; 752 s.
(check this in PDF content)
15
Aaltonen K.J., Vikki L.M., Malmiaara A. et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in the treatment of rheumatoid arthritis. PLoS ONE. 2012; 7:e30275.
(check this in PDF content)
16
Alonso-Ruiz A., Pijoan J.I., Ansuategui E. et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders. 2008; 9: 52.
(check this in PDF content)
17
Baraliakos X., Listing J., Brandt J. et al. Persistent clinical response in patients with ankylosing spondylitis after 4 years of therapy with anti-TNF-monoclonal antibody infliximab. Ann. Rheum. Dis. 2005; 64 (3): 1055 (abstract).
(check this in PDF content)
18
Beevor C.P., Hull R., Thomas A. et al. Anti TNFa therapy reduce emergency health services usage. Ann Rheum Dis. 2006; 65 (II): 176.
(check this in PDF content)
19
Bergman G.J., Hochberg M.C., Boers M. et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to diseasemodifying antirheumatic drugs. Semin Arthritis Rheum. 2010; 39: 425-441.
(check this in PDF content)
20
Bongartz T., Sutton A.J., Sweeting M.J. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 17: 2275-2285.
(check this in PDF content)
21
Heijde D., Sieper J., Maksymowych W. et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 2011; 70: 905-8. DOI:10.1136/ard.2011.151563.
(check this in PDF content)
22
Devine E.B., Alfonso-Cristanchp R., Sullivan S.D. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy. 2011; 31: 39-51.
(check this in PDF content)
23
Fransen J., Stucki G., van Reil P.L. Rheumatoid arthritis measures. Arthritis Rheum. 2003; 49: 214-24.
(check this in PDF content)
24
Gallego-Galisteo M., Villa-Rubio A., Alergre-del Rau E. et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2011; on line.
(check this in PDF content)
25
Garrett S.L., Jenkinson T.R., Whitelock H.C. et al. A new approach to defining disease status in ankylosing spondylitis: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J. Rheumatol. 1994; 21: 2286-91.
(check this in PDF content)
26
Gartlehner G., Hansen R.A., Jonas B.L. et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol. 2006; 3: 23982407l.
(check this in PDF content)
27
Gartlehner G., Thieda P., Morgan L.C. et al. Drug class review. Targeted Immune Modulators. Cecil G Sheps Center for Health Services Research. Oregon Health Science University. 2009.
(check this in PDF content)
28
Gomez-Reino J.J., Dasgupta B., Haugeberg G. et al. Mortality rate is reduced in RA patients treated with TNF antagonists. Data from Biobadaser. Ann Rheum Dis. 2006; 65 (II): 318.
(check this in PDF content)
29
Guyot P., Taylor P., Christensen R. et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Research Ther. 2011; 13: R204.
(check this in PDF content)
30
Kawalec P., Mikrut A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2013; 32: 1415-1424.
(check this in PDF content)
31
Kristensen L.E., Christensen R., Biddal H. et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol. 2007; 36: 411-417.
(check this in PDF content)
32
Kristensen L.E., Jakobsen A.K., Bartels E.M. et al. The number needed to treat for secondgeneration biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol. 2010; May 5.
(check this in PDF content)
33
Leombruno J.P., Einarson T.R., Keystone E.C. The safety of antitumor necrosis factor tretments in rheumatoid arthritis: meta and exposure adjusted pooled analysis of serious adverse events. Ann Rheum Dis. 2008; 27 Aug.
(check this in PDF content)
34
Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P. et al. Birmingham Vasculitis Activity Score (BVAS). Q.J.Med. 1994; 87 (11): 671-8.
(check this in PDF content)
35
Mandema J.W., Salinger D.H., Baumgartner S.W., Gibbs M.A. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol&Ther. 2011; 90: 828-835.
(check this in PDF content)
36
Mease P.J., Antoni C.E., Gladman D.D. et al. Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis. 2005; 64: 1149-54.
(check this in PDF content)
37
Nam J.L., Winthrop K.L., Van Vollenhoven et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010; 69: 976-986.
(check this in PDF content)
38
Nixon R.M., Bansback N., Brennan A. Using mixed treatment comparison and meta-regression to perform indirect comparisons to estimate efficacy of biologic treatment in rheumatoid arthritis. Stat Med. 2007; 26: 1237-1254.
(check this in PDF content)
39
Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan; 38 (1): 44-8. DOI: http:// dx.doi.org/10.1002/art.1780380107.
(check this in PDF content)
40
Roy S. Cifaldi M.A. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis. 2011; 70 (3): 432.
(check this in PDF content)
41
Salgado E., Maneiro J.R., Carmona L. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and metaanalysis. Ann Rheum Dis. DOI:10.1136/annrheumdis-2012-203116.
(check this in PDF content)
42
Salliot C., Finckh A., Katchamart W. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional diseasemodifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta- analysis. Ann Rheum Dis. 2011; 70: 266-271.
(check this in PDF content)
43
Schmitz S., Adams R., Walsh C. et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatment: a Bayesian approach. Ann Rheum Dis. 2012; 71: 225-230.
(check this in PDF content)
44
Schmitz S., Adams R., Walsh C.D. et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrated differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012; January 31.
(check this in PDF content)
45
Singh J.A., Christensen R., Wells G.A. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. The Cochrane Library. 2009; 4.
(check this in PDF content)
46
Singh J.A., Wells G.A., Christensen R. et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview (Review). The Cocgrane Library. 2011; 2.
(check this in PDF content)
47
Singh J.A., Wells G.A., Christensen R. et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview (Review). The Cocgrane Library. 2012; 3.
(check this in PDF content)
48
Turksta E., Ng S.-K., Scuffham P.A. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011; 27: 1885-1897.
(check this in PDF content)
49
Gestel A.M., Haagsma C.J., van Riel P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998; 41 (10): 1845-50.
(check this in PDF content)
50
Vieira M.C., Wallenstein G., Bradley J. et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis facto inhibitors – a network meta-analisis. Ann Rheum Dis. 2014; 72 (3): 619.
(check this in PDF content)
51
Vieira M.C., Wallenstein G., Bradley J. et al. Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs – a network metaanalysis. Ann Rheum Dis. 2012; 71 (3): 375.
(check this in PDF content)
52
Wiens A., Venson R., Pharm D. et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010; 30: 339-353.
(check this in PDF content)
53
Yazici Y., Moniz Reed D., Rosenblatt L. et al. Number needed to treat (NNT) analysis of randomized controlled trials (RCTS) of biologics in methotrexate-naive patients with early rheumatoid arthritis. Ann Rheum Dis. 2009; 68 (3): 583. Сведения об авторах:
(check this in PDF content)